THOMAS FIRNBERG: Open Payments
NPI 1164597472 · STOCKTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,167 in 85 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $110 · 2025 $3,167
Food & beverage: $3,167
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 28 | $885 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $756 |
| Alkermes, Inc. | 5 | $367 |
| Vanda Pharmaceuticals Inc. | 5 | $295 |
| Janssen Pharmaceuticals, Inc | 3 | $245 |
| E.R. Squibb & Sons, L.L.C. | 7 | $216 |
| Lundbeck LLC | 7 | $143 |
| Eisai Inc. | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
Products named: REXULTI, CAPLYTA, FANAPT, INVEGA SUSTENNA, LYBALVI, COBENFY, ABILIFY MAINTENA, ARISTADA.
Industry payments across CA — which companies pay providers there.
